Difficulty: Medium
Average Score: 62%
Practice
Which drug is most appropriate for the treatment of a patient who presents with Zollinger-Ellison syndrome resulting from a gastrinoma?
Correct answer
B
Rationale
In the treatment of Zollinger-Ellison syndrome caused by a gastrinoma, the most appropriate drug is Omeprazole (option B). Omeprazole belongs to the class of proton pump inhibitors (PPIs) and is highly effective in reducing gastric acid secretion by irreversibly inhibiting the hydrogen-potassium adenosine triphosphatase enzyme system (proton pump) in the gastric parietal cells. This mechanism of action makes Omeprazole particularly beneficial in managing conditions characterized by excessive gastric acid production, such as Zollinger-Ellison syndrome.
Metoclopramide (option A) is a prokinetic agent that enhances gastrointestinal motility and is commonly used for conditions like gastroparesis and gastroesophageal reflux disease. It does not directly address the issue of excessive acid production seen in Zollinger-Ellison syndrome.
Ondansetron (option C) is a serotonin 5-HT3 receptor antagonist primarily used for managing nausea and vomiting, particularly in the setting of chemotherapy or postoperative recovery. It does not have a direct role in reducing gastric acid secretion.
Ranitidine (option D) is an H2 receptor antagonist that competitively inhibits histamine at H2 receptors on the gastric parietal cells, leading to a reduction in gastric acid secretion. While it is effective for conditions like peptic ulcers and gastroesophageal reflux disease, it is not the first-line choice for Zollinger-Ellison syndrome, where PPIs like Omeprazole are preferred due to their stronger and more sustained acid-suppressing effects.
In an educational context, understanding the mechanisms of action of different drugs affecting gastrointestinal secretions is crucial for making appropriate treatment decisions in clinical practice. This knowledge helps healthcare professionals tailor therapy to specific conditions, maximizing therapeutic efficacy while minimizing potential side effects.
Metoclopramide (option A) is a prokinetic agent that enhances gastrointestinal motility and is commonly used for conditions like gastroparesis and gastroesophageal reflux disease. It does not directly address the issue of excessive acid production seen in Zollinger-Ellison syndrome.
Ondansetron (option C) is a serotonin 5-HT3 receptor antagonist primarily used for managing nausea and vomiting, particularly in the setting of chemotherapy or postoperative recovery. It does not have a direct role in reducing gastric acid secretion.
Ranitidine (option D) is an H2 receptor antagonist that competitively inhibits histamine at H2 receptors on the gastric parietal cells, leading to a reduction in gastric acid secretion. While it is effective for conditions like peptic ulcers and gastroesophageal reflux disease, it is not the first-line choice for Zollinger-Ellison syndrome, where PPIs like Omeprazole are preferred due to their stronger and more sustained acid-suppressing effects.
In an educational context, understanding the mechanisms of action of different drugs affecting gastrointestinal secretions is crucial for making appropriate treatment decisions in clinical practice. This knowledge helps healthcare professionals tailor therapy to specific conditions, maximizing therapeutic efficacy while minimizing potential side effects.